Boundless Bio
PublicLast Round
IPO Announced
Mar 28, 2024
Est. Valuation
$355.83M
Total Funding Raised
$377M
Company Overview
Boundless Bio is a clinical-stage oncology company focused on developing innovative therapies that target extrachromosomal DNA to treat patients with oncogene amplified tumors.
Sector
Biotech
AI Layer
Non-AI
Keywords
ecDNA-directed therapy (ecDTx)therapeutics for intractable oncogene amplified cancersmall molecule oncology drugcheckpoint kinase 1 (CHK1) inhibitor for oncologyecDNA-focused drug discovery platformecDNA companion diagnostic assayribonucleotide reductase (RNR) inhibitor for oncologycancer replication stress inhibitorclinical-stage oncology drug developmentpreclinical kinesin degrader program
Boundless Bio Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Boundless Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO Announced | Mar 28, 2024 | ||||
| Series C | May 16, 2023 | ||||
| Grant | Jun 16, 2022 | ||||
| Series B | Apr 28, 2021 | ||||
| Series A | Sep 19, 2019 |
Key People
Founding team and executive leadership
Boundless Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series B, Series C |
| National Cancer Institute | Grant |
| RA Capital Management | Series B, Series C |
| Cancer Grand Challenges | Grant |
| Vertex Ventures HC | Series B, Series C |
| Guggenheim Securities | IPO |
| Heartland Healthcare Capital | Series C |
Boundless Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Firmographic Details
HeadquartersSan Diego, California
Employee Range48
Year Founded2018
Last FundingMar 28, 2024